2022/02 - Capital increase for further product development
Date: Fribourg, 08.02.2022
LS Instruments AG, Fribourg (CH), announces the successful completion of an oversubscribed capital increase.
The company, which specializes in the characterization of nanoparticles, will use the money raised to finance further product developments in order to be able to provide the best solution to solve issues in the developmente of new drugs in the pharmaceutical sector, in particular vaccine, cell and gene therapy analytics.
Founded in 2010 as a public limited company, LS Instruments AG (LSI), a spin-off of the University of Fribourg, is a technology leader in the field of optical characterization of nanoparticles. The patented technology, which was developed in close cooperation with Innosuisse (formerly CTI) and the University of Fribourg, is used in basic research as well as in product development and quality control in various industries. From its location in Fribourg, LSI serves an international clientele in over 34 countries worldwide.
Increasing investments in the pharmaceutical industry, increasing regulatory requirements for medical products, and the recent successful launch of vaccines based on mRNA technology related to COVID-19 have led to a global increase in demand for high-precision nanoparticle analytical solutions.
In collaboration with existing customers and Solvias, a leading international analytical service provider (CRO) in the pharmaceutical sector, LSI has achieved outstanding results in vaccine, cell and gene therapy research.
Thanks to its technological edge, its successfully applied analytical solutions worldwide and a customer demand pick-up, LSI is able to announce the successful completion of an oversubscribed capital increase in December 2021.
The financial resources, which come exclusively from a group of private investors, will be used primarily for product development and international expansion. In this context, several new jobs will be created at the Fribourg site.
"Continuos product development and innovation is essential for a healthy growth" confirms Dario Leumann, CEO. "The already established leadership in the academia confirms the uniqueness of LS Instruments patented technology that provides the solution to difficult issues that nobody else can solve up to now".
Development will be in both, hardware and softward, bringing improved products on the market.
The size of the capital increase has been agreed with the investors not to be disclosed.